Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 754111 + ezabenlimab in advanced solid tumors and NSCLC
NCT03156114Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2017
- Primary completion
- Mar 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of miptenalimab in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and solid tumor (11 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum-tolerated Dose at 21 days, Dose-Limiting Toxicities at 21 days and 1 more. Started Jun 2017; status: completed.
02
Drugs
miptenalimab
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT03156114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03156114.